🇺🇸 FDA
Patent

US 8192741

Method of treating rheumatoid arthritis with an anti-IL-6R antibody

granted A61KA61K2039/505A61K31/4706

Quick answer

US patent 8192741 (Method of treating rheumatoid arthritis with an anti-IL-6R antibody) held by REGENERON PHARMACEUTICALS, INC. expires Mon May 31 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Jun 05 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 31 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K2039/505, A61K31/4706, A61K31/519, A61K31/655